{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:36:10Z","timestamp":1790634970000,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T00:00:00Z","timestamp":1418860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00296-014-3189-6","type":"journal-article","created":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T11:56:21Z","timestamp":1418817381000},"page":"1127-1137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"35","author":[{"given":"Isabel","family":"Castrejon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Piedad","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Est\u00edbaliz","family":"Loza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"P\u00e9rez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,18]]},"reference":[{"issue":"34\u201335","key":"3189_CR1","first-page":"549","volume":"106","author":"AK Tausche","year":"2009","unstructured":"Tausche AK, Jansen TL, Schroder HE, Bornstein SR, Aringer M, Muller-Ladner U (2009) Gout\u2014current diagnosis and treatment. Deutsches Arzteblatt Int 106(34\u201335):549\u2013555. doi: 10.3238\/arztebl.2009.0549","journal-title":"Deutsches Arzteblatt Int"},{"issue":"Suppl 5","key":"3189_CR2","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3949\/ccjm.75.Suppl_5.S9","volume":"75","author":"AL Weaver","year":"2008","unstructured":"Weaver AL (2008) Epidemiology of gout. Cleve Clin J Med 75(Suppl 5):S9\u2013S12","journal-title":"Cleve Clin J Med"},{"key":"3189_CR3","doi-asserted-by":"crossref","first-page":"d7459","DOI":"10.1136\/bmj.d7459","volume":"343","author":"W Lipworth","year":"2011","unstructured":"Lipworth W, Kerridge I, Brett J, Day R (2011) How clinical and research failures lead to suboptimal prescribing: the example of chronic gout. BMJ 343:d7459. doi: 10.1136\/bmj.d7459","journal-title":"BMJ"},{"issue":"21","key":"3189_CR4","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","volume":"64","author":"N Schlesinger","year":"2004","unstructured":"Schlesinger N (2004) Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 64(21):2399\u20132416","journal-title":"Drugs"},{"issue":"4","key":"3189_CR5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","volume":"47","author":"F Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A (2002) Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 47(4):356\u2013360. doi: 10.1002\/art.10511","journal-title":"Arthritis Rheum"},{"issue":"8","key":"3189_CR6","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 64(8):2529\u20132536. doi: 10.1002\/art.34488","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3189_CR7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76(1):47\u201356","journal-title":"Am J Med"},{"issue":"2","key":"3189_CR8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, O\u2019Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63(2):412\u2013421. doi: 10.1002\/art.30119","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"3189_CR9","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/rheumatology\/kep088","volume":"48","author":"NL Edwards","year":"2009","unstructured":"Edwards NL (2009) Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford) 48(Suppl 2):ii15\u2013ii19. doi: 10.1093\/rheumatology\/kep088","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"3189_CR10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/BOR.0b013e32802106b9","volume":"19","author":"E Pascual","year":"2007","unstructured":"Pascual E, Sivera F (2007) Therapeutic advances in gout. Curr Opin Rheumatol 19(2):122\u2013127. doi: 10.1097\/BOR.0b013e32802106b9","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"3189_CR11","first-page":"1290","volume":"28","author":"M Tulder van","year":"2003","unstructured":"van Tulder M, Furlan A, Bombardier C, Bouter L, Editorial Board of the Cochrane Collaboration Back Review G (2003) Updated method guidelines for systematic reviews in the Cochrane collaboration back review group. Spine 28(12):1290\u20131299. doi: 10.1097\/01.BRS.0000065484.95996.AF","journal-title":"Spine"},{"issue":"1","key":"3189_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"issue":"2","key":"3189_CR13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/11535770-000000000-00000","volume":"29","author":"M Stevenson","year":"2011","unstructured":"Stevenson M, Pandor A (2011) Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics 29(2):133\u2013140. doi: 10.2165\/11535770-000000000-00000","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 3","key":"3189_CR14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3310\/hta13suppl3-06","volume":"13","author":"M Stevenson","year":"2009","unstructured":"Stevenson M, Pandor A (2009) Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal. Health Technol Assess 13(Suppl 3):37\u201342. doi: 10.3310\/hta13suppl3\/06","journal-title":"Health Technol Assess"},{"issue":"1","key":"3189_CR15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/187221307779815020","volume":"1","author":"KH Yu","year":"2007","unstructured":"Yu KH (2007) Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Pat Inflamm Allergy Drug Discov 1(1):69\u201375","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"issue":"5","key":"3189_CR16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/ar3110","volume":"12","author":"JA Singh","year":"2010","unstructured":"Singh JA (2010) Advances in gout: some answers, more questions. Arthritis Res Ther 12(5):136. doi: 10.1186\/ar3110","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"3189_CR17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59(11):1540\u20131548. doi: 10.1002\/art.24209","journal-title":"Arthritis Rheum"},{"issue":"6","key":"3189_CR18","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, Brouwers JR (2009) A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600\u00a0mg\/day versus benzbromarone 100\u2013200\u00a0mg\/day in patients with gout. Ann Rheum Dis 68(6):892\u2013897. doi: 10.1136\/ard.2008.091462","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3189_CR19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, van de Laar MA, Brouwers JR (2009) Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 68(1):51\u201356. doi: 10.1136\/ard.2007.083071","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3189_CR20","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12(2):R63. doi: 10.1186\/ar2978","journal-title":"Arthritis Res Ther"},{"issue":"23","key":"3189_CR21","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450\u20132461. doi: doi: 10.1056\/NEJMoa050373","journal-title":"N Engl J Med"},{"issue":"4 Suppl 2","key":"3189_CR22","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/RHU.0b013e31822541d0","volume":"17","author":"N Kamatani","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y (2011) Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. J Clin Rheumatol 17(4 Suppl 2):S50\u2013S56. doi: 10.1097\/RHU.0b013e31822541d0","journal-title":"J Clin Rheumatol"},{"issue":"4 Suppl 2","key":"3189_CR23","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/RHU.0b013e31821d36cc","volume":"17","author":"N Kamatani","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y (2011) An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol 17(4 Suppl 2):S13\u2013S18. doi: 10.1097\/RHU.0b013e31821d36cc","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"3189_CR24","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20(3):895\u2013900","journal-title":"Arthritis Rheum"},{"key":"3189_CR25","doi-asserted-by":"crossref","first-page":"842","DOI":"10.7326\/0003-4819-62-4-842","volume":"62","author":"JB Wyngaarden","year":"1965","unstructured":"Wyngaarden JB, Rundles RW, Metz EN (1965) Allopurinol in the treatment of gout. Ann Intern Med 62:842\u2013847","journal-title":"Ann Intern Med"}],"updated-by":[{"DOI":"10.1007\/s00296-015-3264-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T00:00:00Z","timestamp":1429574400000}}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-014-3189-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-014-3189-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-014-3189-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T14:20:18Z","timestamp":1650810018000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-014-3189-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,18]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["3189"],"URL":"https:\/\/doi.org\/10.1007\/s00296-014-3189-6","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,18]]}}}